« Back to Record
Citation APA

Brandão, M., Zugazagoitia, J., Dingemans, A. M. A., Duruisseaux, M., Parent, P., Juan-Vidal, O., Spira, A. I., Vicier, C., Zalcman, G., Barasa, B., Yan, C., Doze, P., Joe, A. K., Laus, G., & Felip, E. (2024). Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations ( MET ex14). Journal of clinical oncology, 42(16_suppl), 8583-8583. doi:10.1200/JCO.2024.42.16_suppl.8583


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401699

Brandão, M., Zugazagoitia, J., Dingemans, A. M. A., Duruisseaux, M., Parent, P., Juan-Vidal, O., Spira, A. I., Vicier, C., Zalcman, G., Barasa, B., Yan, C., Doze, P., Joe, A. K., Laus, G., & Felip, E. (2024). Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations ( MET ex14). Journal of clinical oncology, 42(16_suppl), 8583-8583. doi:10.1200/JCO.2024.42.16_suppl.8583